Barclays PLC Nymox Pharmaceutical Corp Transaction History

Barclays PLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.95 - $2.1 $4,793 - $10,596	-5,046 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$1.3 - $2.23 $5,019 - $8,610	-3,861 Reduced 43.35%	5,046 $10,000
Q2 2021 Aug 13, 2021	SELL	$1.46 - $2.48 $38,618 - $65,598	-26,451 Reduced 74.81%	8,907 $14,000
Q1 2021 May 13, 2021	BUY	$2.22 - $3.39 $48,187 - $73,583	21,706 Added 159.0%	35,358 $79,000
Q4 2020 Feb 11, 2021	SELL	$1.84 - $2.83 $9,711 - $14,936	-5,278 Reduced 27.88%	13,652 $34,000
Q3 2020 Nov 12, 2020	SELL	$2.3 - $3.66 $6,069 - $9,658	-2,639 Reduced 12.24%	18,930 $47,000
Q2 2020 Aug 12, 2020	BUY	$2.1 - $4.6 $45,294 - $99,217	21,569 New	21,569 $77,000
Q3 2019 Nov 14, 2019	SELL	$1.41 - $2.12 $1 - $2	-1 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.33 - $2.12 $12,315 - $19,631	-9,260 Reduced 99.99%	1 $0
Q1 2019 May 15, 2019	BUY	$1.57 - $2.71 $13,756 - $23,745	8,762 Added 1755.91%	9,261 $18,000
Q4 2018 Feb 14, 2019	SELL	$1.31 - $2.53 $15,459 - $29,856	-11,801 Reduced 95.94%	499 $0
Q3 2018 Nov 14, 2018	BUY	$2.46 - $3.7 $24,425 - $36,737	9,929 Added 418.77%	12,300 $30,000
Q2 2018 Aug 14, 2018	SELL	$3.12 - $4.33 $14,064 - $19,519	-4,508 Reduced 65.53%	2,371 $8,000
Q1 2018 May 15, 2018	BUY	$3.09 - $4.43 $4,115 - $5,900	1,332 Added 24.01%	6,879 $28,000
Q4 2017 Feb 14, 2018	BUY	$3.29 - $4.06 $15,930 - $19,658	4,842 Added 686.81%	5,547 $19,000
Q3 2017 Nov 14, 2017	BUY	$3.36 - $4.02 $2,368 - $2,834	705	705 $3,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.